{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:23:54Z","timestamp":1789017834716,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"am","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001320","name":"Roswell Park Comprehensive Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001320","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"National Cancer Institute Division of Cancer Epidemiology and Genetics","doi-asserted-by":"publisher","award":["P30CA016056"],"award-info":[{"award-number":["P30CA016056"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.clml.2024.10.014","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T07:49:42Z","timestamp":1730274582000},"page":"67-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Clinical Characteristics and Survival Outcomes of Patients With Primary and Secondary Plasma Cell Leukemia According to the 2021 Definition: A Single Center Retrospective Study"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6948-8057","authenticated-orcid":false,"given":"Khalid","family":"Shalaby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhan","family":"Azad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristopher","family":"Attwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1778-0010","authenticated-orcid":false,"given":"Jens","family":"Hillengass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clml.2024.10.014_bib0001","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1182\/blood-2014-03-565051","article-title":"Trends in survival of patients with primary plasma cell leukemia: a population-based analysis","volume":"124","author":"Gonsalves","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2024.10.014_bib0002","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/ejh.12907","article-title":"Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish myeloma register","volume":"99","author":"Nahi","year":"2017","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2024.10.014_bib0003","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00414-6","article-title":"A clinical perspective on plasma cell leukemia; current status and future directions","volume":"11","author":"Tuazon","year":"2021","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.clml.2024.10.014_bib0004","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41375-023-02100-x","article-title":"Chaulagain CP. Real world analysis on the determinants of survival in primary plasma cell leukemia in the United States","volume":"38","author":"Saba","year":"2024","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.clml.2024.10.014_bib0005","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1002\/cncr.24700","article-title":"Primary plasma cell leukemia: a surveillance, epidemiology, and end results database analysis between 1973 and 2004","volume":"115","author":"Ramsingh","year":"2009","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.clml.2024.10.014_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-021-00587-0","article-title":"Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage","volume":"11","author":"Fern\u00e1ndez de Larrea","year":"2021","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.clml.2024.10.014_bib0007","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41408-018-0140-1","article-title":"Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma","volume":"8","author":"Ravi","year":"2018","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.clml.2024.10.014_bib0008","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.3324\/haematol.2016.158303","article-title":"Prognostic impact of circulating plasma cells in patients with multiple myeloma: Implications for plasma cell leukemia definition","volume":"102","author":"Granell","year":"2017","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.clml.2024.10.014_bib0009","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/leu.2012.336","article-title":"Plasma cell leukemia: Consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group","volume":"27","author":"Fern\u00e1ndez De Larrea","year":"2013","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2024.10.014_bib0010","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.clml.2022.12.002","article-title":"The current state of knowledge about evolution of multiple myeloma to plasma cell leukemia","volume":"23","author":"Jurczyszyn","year":"2023","journal-title":"Clin Lymphoma, Myeloma Leuk."},{"issue":"5","key":"10.1016\/j.clml.2024.10.014_bib0011","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3324\/haematol.2009.013334","article-title":"Primary plasma cell leukemia and autologous stem cell transplantation","volume":"95","author":"Drake","year":"2010","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.clml.2024.10.014_bib0012","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3324\/haematol.2021.280568","article-title":"Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling","volume":"108","author":"Lawless","year":"2023","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.clml.2024.10.014_bib0013","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/bjh.15092","article-title":"Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients","volume":"180","author":"Jurczyszyn","year":"2018","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2024.10.014_bib0014","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1080\/10428194.2018.1473574","article-title":"Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients","volume":"60","author":"Jurczyszyn","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.clml.2024.10.014_bib0015","article-title":"Clinical and cytogenetic characteristics of primary and secondary plasma cell leukemia under the new IMWG definition criteria: a retrospective study","volume":"28","author":"Guan","year":"2023","journal-title":"Hematol (United Kingdom)"},{"issue":"5","key":"10.1016\/j.clml.2024.10.014_bib0016","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.12689","article-title":"Nestin expression throughout multistep pathogenesis of multiple myeloma","volume":"164","author":"Svachova","year":"2014","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.clml.2024.10.014_bib0017","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1365-2141.2006.06237.x","article-title":"Significant increase of CKS1B amplification from monoclonal gammopathy of undetermined significance to multiple myeloma and plasma cell leukaemia as demonstrated by interphase fluorescence in situ hybridisation","volume":"134","author":"Chang","year":"2006","journal-title":"Br J Haematol"},{"issue":"17","key":"10.1016\/j.clml.2024.10.014_bib0018","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1182\/blood.2021014968","article-title":"Primary plasma cell leukemias displaying t (11;14) have specific genomic, transcriptional, and clinical features","volume":"139","author":"Cazaubiel","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2024.10.014_bib0019","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.leukres.2008.06.027","article-title":"Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia","volume":"33","author":"Chang","year":"2009","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.clml.2024.10.014_bib0020","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/leu.2017.179","article-title":"Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients","volume":"32","author":"Shah","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2024.10.014_bib0021","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2991\/chi.k.200706.002","article-title":"Plasma cell leukemia \u2013facts and controversies: more questions than answers?","volume":"2","author":"Suska","year":"2020","journal-title":"Clin Hematol Int"},{"issue":"2","key":"10.1016\/j.clml.2024.10.014_bib0022","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ajh.23600","article-title":"Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: analysis of the Greek myeloma study group","volume":"89","author":"Katodritou","year":"2014","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.clml.2024.10.014_bib0023","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/ajh.26891","article-title":"Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab-based quadruplets: A multicenter study by the Greek myeloma study group","volume":"98","author":"Katodritou","year":"2023","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.clml.2024.10.014_bib0024","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/cncr.31718","article-title":"Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents","volume":"125","author":"Mina","year":"2019","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.clml.2024.10.014_bib0025","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41409-018-0392-1","article-title":"Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs","volume":"54","author":"Gowda","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.clml.2024.10.014_bib0026","doi-asserted-by":"crossref","first-page":"e652","DOI":"10.1016\/j.clml.2020.05.014","article-title":"Primary plasma cell leukemia: real-world retrospective study of 46 patients from a single-center study in China","volume":"20","author":"Yu","year":"2020","journal-title":"Clin Lymphoma, Myeloma Leuk."},{"issue":"8","key":"10.1016\/j.clml.2024.10.014_bib0027","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.clml.2021.03.013","article-title":"KD-PACE salvage therapy for aggressive relapsed refractory multiple myeloma, plasma cell leukemia and extramedullary myeloma","volume":"21","author":"Alsouqi","year":"2021","journal-title":"Clin Lymphoma, Myeloma Leuk."},{"issue":"5","key":"10.1016\/j.clml.2024.10.014_bib0028","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.clml.2021.01.002","article-title":"Efficacy of daratumumab-based regimens for the treatment of plasma cell leukemia","volume":"21","author":"Parrondo","year":"2021","journal-title":"Clin Lymphoma, Myeloma Leuk."},{"issue":"23","key":"10.1016\/j.clml.2024.10.014_bib0029","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.22.02567","article-title":"Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk multiple myeloma","volume":"41","author":"Kaiser","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.10.014_bib0030","first-page":"1","article-title":"Case report: Plasma cell leukemia secondary to multiple myeloma successfully treated with anti-BCMA CAR-T cell therapy","volume":"12","author":"Deng","year":"2019","journal-title":"Front Oncol. 2022"},{"issue":"21","key":"10.1016\/j.clml.2024.10.014_bib0031","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1182\/blood.2020008936","article-title":"A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma","volume":"137","author":"Wang","year":"2021","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024023991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024023991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T06:39:32Z","timestamp":1736059172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024023991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2152265024023991"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.10.014","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Characteristics and Survival Outcomes of Patients With Primary and Secondary Plasma Cell Leukemia According to the 2021 Definition: A Single Center Retrospective Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}